Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
25.09.2025 15:28:13
|
Eli Lilly Cancels Phase 2b Study Of Bimagrumab And Tirzepatide For Strategic Reasons
(RTTNews) - Eli Lilly and Company (LLY) has decided to halt a Phase 2b obesity study, citing strategic business considerations, according to ClinicalTrials.gov.
The study was designed to evaluate the efficacy and safety of bimagrumab, tirzepatide, and their combination in reducing body weight in adults with obesity or overweight and type 2 diabetes.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 733,80 | 0,66% |
|